# US 8,784,841 B2 · Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,841 B2
- Document ID: US8784841B2
- Status: Granted
- Kind: B2
- Application number: 12/989,608
- Filed: 2009-04-27
- Published: 2011-02-17
- Granted: 2014-07-22
- Earliest claimed: 2008-04-25
- Assignees: Ipsen Pharma S.A.S.
- Applicants: Christine Favre; Michel Auguet; Piere-Etienne Chabrier De Lassauniere
- Inventors: Christine Favre; Michel Auguet; Piere-Etienne Chabrier De Lassauniere
- Web page: https://patentgrep.com/patent/US8784841B2

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.

## Claims

### Claim 1

A method of treating pain associated with diabetic neuropathy comprising administering at least one botulinum neurotoxin to a painless site in the upper or lower limb to a subject in need thereof,
wherein said administration alleviates pain on the contralateral side of the body, distant from the site of administration, and said botulinum neurotoxin is not administered to the central nervous system, thereby alleviating pain on the contralateral side of the body.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said diabetic neuropathy is in the upper limb.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said diabetic neuropathy is in the lower limb.

### Claim 4 (depends on 1)

The method according claim 1, wherein said administration is into a limb.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the administration is into a hand or a foot.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said administration is into the palm of the hand or the sole of the foot.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said administration is limited to one side of the body.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said administration is no more than once a month, once every six weeks, or once every 8 weeks.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said administration is sub-cutaneous, intra-muscular, intradermal or transdermal administration.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the botulinum neurotoxin is type A, A1, A2, A3, A4, B, C, C1, D, E, F, or G.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the botulinum neurotoxin is type A1.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said botulinum neurotoxin is administered at a dose between 1 U and 1500 U.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said dose is between 100 and 500 U.